A new cancer drug costs as much as a home down payment each month. Doctors say that's greed, not health care

A new cancer drug, Daraxonrasib, costs Canadian patient James Howard $90,000 a month, a price that rivals a home down payment and raises significant concerns about the affordability of modern medicine. Oncologists argue that these exorbitant costs are not only financially burdensome for patients but also threaten to strain public health care resources. This situation underscores a broader issue where high drug prices are increasingly seen as a form of greed that compromises patient care and healthcare equity.